<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="39169"><DrugName>luminespib</DrugName><DrugNamesKey><Name id="42999286">luminespib</Name><Name id="43030375">luminespib mesylate</Name></DrugNamesKey><DrugSynonyms><Name><Value>CCT-018159</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>RBT-0028535</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>PH-3</Value></Name><Name><Value>VER-28535</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>VER-49009</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>CCT-066950</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>CCT-066952</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>CCT-066965</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>CCT-072440</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>CCT-0669963</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>RBT-0027129</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>RBT-0036283</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>RBT-0045856</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>Hsp 90 inhibitors (cancer), Vernalis/Novartis</Value></Name><Name><Value>Hsp 90 inhibitors, RiboTargets/Institute of Cancer Research</Value></Name><Name><Value>Hsp 90 inhibitors, Cancer Research Ventures/Vernalis</Value></Name><Name><Value>Hsp 90 inhibitors, Institute of Cancer Research/Vernalis</Value></Name><Name><Value>G-3130</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>G-3129</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>VER-50589</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>VER-27129</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>VER-49537</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>VER-510747</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>NVP-AUY-922</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>VER-52296</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>VER-45864</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>VER-51000</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>AUY-922</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>luminespib</Value><Types><Type>USAN</Type><Type>INN</Type></Types></Name><Name><Value>luminespib mesylate</Value><Types><Type>USAN</Type></Types></Name><Name><Value>171009-07-7</Value><Types><Type>CAS RN</Type></Types></Name><Name><Value>747412-49-3</Value><Types><Type>CAS RN</Type></Types></Name><Name><Value>1051919-26-6</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="24962">RiboTargets Ltd</CompanyOriginator><CompaniesPrimary><Company id="15262">Vernalis plc</Company></CompaniesPrimary><CompaniesSecondary><Company id="15935">Cancer Research Ventures Ltd</Company><Company id="21072">Institute of Cancer Research UK</Company><Company id="23137">Novartis AG</Company><Company id="24962">RiboTargets Ltd</Company></CompaniesSecondary><CrossReferences><SourceEntity id="39169" type="Drug"><TargetEntity id="463332" type="siDrug">Luminespib</TargetEntity><TargetEntity id="401173" type="siDrug">VER-49009</TargetEntity></SourceEntity><SourceEntity id="15262" type="Company"><TargetEntity id="4295894372" type="organizationId">Vernalis Ltd</TargetEntity></SourceEntity><SourceEntity id="15935" type="Company"><TargetEntity id="4296790798" type="organizationId">Cancer Research Ventures Ltd</TargetEntity></SourceEntity><SourceEntity id="21072" type="Company"><TargetEntity id="4297014876" type="organizationId">Institute of Cancer Research: Royal Cancer Hospital</TargetEntity></SourceEntity><SourceEntity id="23137" type="Company"><TargetEntity id="4295890628" type="organizationId">Novartis AG</TargetEntity></SourceEntity><SourceEntity id="24962" type="Company"><TargetEntity id="5031643675" type="organizationId">Ribotargets Ltd</TargetEntity></SourceEntity><SourceEntity id="1262" type="ciIndication"><TargetEntity id="10061873" type="MEDDRA"/><TargetEntity id="D002289" type="MeSH"/><TargetEntity id="-1730468577" type="omicsDisease"/><TargetEntity id="612" type="siCondition"/></SourceEntity><SourceEntity id="127" type="ciIndication"><TargetEntity id="C16" type="ICD10"/><TargetEntity id="151" type="ICD9"/><TargetEntity id="10017758" type="MEDDRA"/><TargetEntity id="D013274" type="MeSH"/><TargetEntity id="-2031094615" type="omicsDisease"/><TargetEntity id="646" type="siCondition"/></SourceEntity><SourceEntity id="1729" type="ciIndication"><TargetEntity id="-903738911" type="omicsDisease"/><TargetEntity id="1883" type="siCondition"/></SourceEntity><SourceEntity id="1828" type="ciIndication"><TargetEntity id="C90.0" type="ICD10"/><TargetEntity id="10028228" type="MEDDRA"/><TargetEntity id="D009101" type="MeSH"/><TargetEntity id="29073" type="ORPHANET"/><TargetEntity id="-18870694" type="omicsDisease"/><TargetEntity id="710" type="siCondition"/></SourceEntity><SourceEntity id="203" type="ciIndication"><TargetEntity id="10025310" type="MEDDRA"/><TargetEntity id="D008223" type="MeSH"/><TargetEntity id="-386134440" type="omicsDisease"/><TargetEntity id="698" type="siCondition"/></SourceEntity><SourceEntity id="2399" type="ciIndication"><TargetEntity id="10001141" type="MEDDRA"/><TargetEntity id="D000230" type="MeSH"/><TargetEntity id="-1620546969" type="omicsDisease"/><TargetEntity id="656" type="siCondition"/></SourceEntity><SourceEntity id="2436" type="ciIndication"><TargetEntity id="D75.81" type="ICD10"/><TargetEntity id="10028537" type="MEDDRA"/><TargetEntity id="D055728" type="MeSH"/><TargetEntity id="-1044236653" type="omicsDisease"/><TargetEntity id="1634" type="siCondition"/></SourceEntity><SourceEntity id="3205" type="ciIndication"><TargetEntity id="10051066" type="MEDDRA"/><TargetEntity id="D046152" type="MeSH"/><TargetEntity id="44890" type="ORPHANET"/><TargetEntity id="-1743085733" type="omicsDisease"/><TargetEntity id="668" type="siCondition"/></SourceEntity><SourceEntity id="3669" type="ciIndication"><TargetEntity id="631" type="siCondition"/></SourceEntity><SourceEntity id="49" type="ciIndication"><TargetEntity id="C50" type="ICD10"/><TargetEntity id="10006279" type="MEDDRA"/><TargetEntity id="D001943" type="MeSH"/><TargetEntity id="-436099203" type="omicsDisease"/><TargetEntity id="588" type="siCondition"/></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"/></SourceEntity><SourceEntity id="725" type="ciIndication"><TargetEntity id="1164" type="siCondition"/></SourceEntity><SourceEntity id="989" type="ciIndication"><TargetEntity id="10061451" type="MEDDRA"/><TargetEntity id="D015179" type="MeSH"/><TargetEntity id="-1280257855" type="omicsDisease"/><TargetEntity id="594" type="siCondition"/></SourceEntity><SourceEntity id="61" type="Action"><TargetEntity id="885" type="Mechanism">Angiogenesis Inhibitors</TargetEntity></SourceEntity><SourceEntity id="8012" type="Action"><TargetEntity id="1513" type="Mechanism">Heat Shock Protein 90 (Hsp90) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="529" type="Action"><TargetEntity id="2936" type="Mechanism">ATPase Inhibitors</TargetEntity></SourceEntity><SourceEntity id="1589" type="Action"><TargetEntity id="1062" type="Mechanism">Apoptosis Inducers</TargetEntity></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="S">Suspended</PhaseHighest><IndicationsPrimary><Indication id="651">Cancer</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="1262">Non-small-cell lung cancer</Indication><Indication id="127">Stomach tumor</Indication><Indication id="1729">B-cell acute lymphoblastic leukemia</Indication><Indication id="1828">Multiple myeloma</Indication><Indication id="203">Lymphoma</Indication><Indication id="2399">Adenocarcinoma</Indication><Indication id="2436">Myelofibrosis</Indication><Indication id="3205">Gastrointestinal stromal tumor</Indication><Indication id="3669">Metastatic pancreas cancer</Indication><Indication id="3713">Advanced solid tumor</Indication><Indication id="49">Breast tumor</Indication><Indication id="725">Solid tumor</Indication><Indication id="989">Colorectal tumor</Indication></IndicationsSecondary><ActionsPrimary><Action id="529">ATPase inhibitor</Action><Action id="8012">Hsp 90 inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="61">Angiogenesis inhibitor</Action><Action id="1589">Apoptosis stimulator</Action><Action id="1545">Anticancer</Action><Action id="7293">Synergist</Action></ActionsSecondary><Technologies><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2018-10-23T07:52:51.000Z</LastModificationDate><ChangeDateLast>2018-10-15T00:00:00.000Z</ChangeDateLast><AddedDate>2002-04-10T09:59:25.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="15262" linkType="Company"&gt;Vernalis&lt;/ulink&gt;,  a subsidiary of &lt;ulink linkID="17808" linkType="Company"&gt;Ligand&lt;/ulink&gt;, was investigating luminespib (NVP-AUY-922; AUY-922; VER-52296; structure shown), the lead from a program of Hsp 90 chaperone family ATPase activity inhibitors,  for the potential  iv treatment of cancer, primarily non-small-cell lung cancer (NSCLC), gastric cancer, metastatic pancreatic cancer , lymphoma and adenocarcinoma lung cancer [&lt;ulink linkID="446766" linkType="Reference"&gt;446766&lt;/ulink&gt;], [&lt;ulink linkID="559635" linkType="Reference"&gt;559635&lt;/ulink&gt;], [&lt;ulink linkID="775402" linkType="Reference"&gt;775402&lt;/ulink&gt;], [&lt;ulink linkID="845043" linkType="Reference"&gt;845043&lt;/ulink&gt;], [&lt;ulink linkID="1086229" linkType="Reference"&gt;1086229&lt;/ulink&gt;], [&lt;ulink linkID="1325956" linkType="Reference"&gt;1325956&lt;/ulink&gt;],  [&lt;ulink linkID="1249920" linkType="Reference"&gt;1249920&lt;/ulink&gt;], [&lt;ulink linkID="1248265" linkType="Reference"&gt;1248265&lt;/ulink&gt;], [&lt;ulink linkID="1615536" linkType="Reference"&gt;1615536&lt;/ulink&gt;], [&lt;ulink linkID="2081358" linkType="Reference"&gt;2081358&lt;/ulink&gt;]. In December 2014,  Novartis stopped all development of luminespib and returned all rights back to Vernalis; at that time, the return of program data was expected in early 2015 after which Vernalis would decide on the next steps forward [&lt;ulink linkID="1622106" linkType="Reference"&gt;1622106&lt;/ulink&gt;]. By August 2015, Vernalis had decided not to futher invest in the development of the drug and was actively seeking a partner [&lt;ulink linkID="1683196" linkType="Reference"&gt;1683196&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;ulink linkID="23137" linkType="Company"&gt;Novartis&lt;/ulink&gt;, under license from Vernalis (formerly &lt;ulink linkID="24962" linkType="Company"&gt;RiboTargets&lt;/ulink&gt;), was previously developing luminespib  for the potential  iv treatment of cancer, primarily non-small-cell lung cancer (NSCLC), gastric cancer, metastatic pancreatic cancer , lymphoma and adenocarcinoma lung cancer [&lt;ulink linkID="446766" linkType="Reference"&gt;446766&lt;/ulink&gt;], [&lt;ulink linkID="559635" linkType="Reference"&gt;559635&lt;/ulink&gt;], [&lt;ulink linkID="775402" linkType="Reference"&gt;775402&lt;/ulink&gt;], [&lt;ulink linkID="845043" linkType="Reference"&gt;845043&lt;/ulink&gt;], [&lt;ulink linkID="1086229" linkType="Reference"&gt;1086229&lt;/ulink&gt;], [&lt;ulink linkID="1325956" linkType="Reference"&gt;1325956&lt;/ulink&gt;],  [&lt;ulink linkID="1249920" linkType="Reference"&gt;1249920&lt;/ulink&gt;], [&lt;ulink linkID="1248265" linkType="Reference"&gt;1248265&lt;/ulink&gt;], [&lt;ulink linkID="1615536" linkType="Reference"&gt;1615536&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;A phase II trial in gastric cancer was initiated in March 2010 [&lt;ulink linkID="1086229" linkType="Reference"&gt;1086229&lt;/ulink&gt;]. phase II development in gastric cancer was  ongoing in April 2012 [&lt;ulink linkID="1275518" linkType="Reference"&gt;1275518&lt;/ulink&gt;]. In October 2010, the company began a phase II trial in NSCLC [&lt;ulink linkID="1145478" linkType="Reference"&gt;1145478&lt;/ulink&gt;]; in September 2012, data were presented [&lt;ulink linkID="1325956" linkType="Reference"&gt;1325956&lt;/ulink&gt;].   In January 2012, a phase II metastatic pancreatic adenocarcinoma trial began [&lt;ulink linkID="1248265" linkType="Reference"&gt;1248265&lt;/ulink&gt;]. In September 2012, a phase II trial in  refractory or recurrent lymphoma was initiated [&lt;ulink linkID="1249920" linkType="Reference"&gt;1249920&lt;/ulink&gt;]. In January 2014, the company expected filing regulatory applications in 2018 or later [&lt;ulink linkID="1519399" linkType="Reference"&gt;1519399&lt;/ulink&gt;]. In October 2014, a phase II trial for adenocarcinoma lung cancer was planned to be initiated in China in  January 2015;  by March 2015, the study was initiated  [&lt;ulink linkID="1615536" linkType="Reference"&gt;1615536&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Luminespib was also being developed in other indications, including breast cancer, gastrointestinal stromal tumor, myefibrosis and colorectal cancer. A phase II study in breast cancer began in September 2010 [&lt;ulink linkID="1171440" linkType="Reference"&gt;1171440&lt;/ulink&gt;] and a second phase II study in breast cancer began in April 2012 [&lt;ulink linkID="1275518" linkType="Reference"&gt;1275518&lt;/ulink&gt;]. In December 2011, a phase II gastrointestinal stromal tumor trial began [&lt;ulink linkID="1235413" linkType="Reference"&gt;1235413&lt;/ulink&gt;]. A further  phase II trial began in myelofibrosis in August 2012 [&lt;ulink linkID="1325783" linkType="Reference"&gt;1325783&lt;/ulink&gt;]; and  in February 2011, a phase I trial began in patients with colorectal cancer  [&lt;ulink linkID="1171417" linkType="Reference"&gt;1171417&lt;/ulink&gt;]. In September 2013, Novartis filed a clinical trial application in China, presumed to be for solid tumor [&lt;ulink linkID="1474618" linkType="Reference"&gt;1474618&lt;/ulink&gt;], [&lt;ulink linkID="1473712" linkType="Reference"&gt;1473712&lt;/ulink&gt;]. However, in December 2014, Novartis ceased the  development of the drug and reverted all the rights back to Vernalis  [&lt;ulink linkID="1622106" linkType="Reference"&gt;1622106&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Novartis was previously developing luminespib in combination with &lt;ulink linkID="15954" linkType="Drug"&gt;bortezomib&lt;/ulink&gt; for the potential treatment of multiple myeloma [&lt;ulink linkID="925021" linkType="Reference"&gt;925021&lt;/ulink&gt;]; however,  a high percentage of patients that received the combination experienced DLTs   and the study was discontinued [&lt;ulink linkID="1302070" linkType="Reference"&gt;1302070&lt;/ulink&gt;].  &lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;In January 2012, filings in solid tumors were expected to be in or after 2016 [&lt;ulink linkID="1257608" linkType="Reference"&gt;1257608&lt;/ulink&gt;]. In January 2014, the company expected filing regulatory applications in 2018 or later for solid tumors [&lt;ulink linkID="1519399" linkType="Reference"&gt;1519399&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Metastatic pancreatic cancer&lt;/subtitle&gt;In January 2012, an open-label, phase II study (&lt;ulink linkID="82933" linkType="Protocol"&gt;NCT01484860&lt;/ulink&gt;; DDP-922) began in Canada to assess the safety and efficacy of luminespib in patients with metastatic pancreatic adenocarcinoma (expected n = 37); at that time, the trial was scheduled to  complete in August 2013 [&lt;ulink linkID="1248265" linkType="Reference"&gt;1248265&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Lymphoma&lt;/subtitle&gt;In December 2011, an open-label, phase II study (&lt;ulink linkID="82982" linkType="Protocol"&gt;NCT01485536&lt;/ulink&gt;; 2011-0467) was planned in patients with refractory or recurrent lymphoma (expected n = 42) in the US, to assess the safety and efficacy of luminespib. At that time, the study was expected to begin in April 2012, and complete in April 2015. The trial was initiated in September 2012 [&lt;ulink linkID="1249920" linkType="Reference"&gt;1249920&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Non-small-cell lung cancer&lt;/subtitle&gt;In September 2015, data were presented from a multicenter, open-label, phase II trial (NCT01752400) of AUY-922 in ALK-positive non-small cell lung cancer patients previously treated with at least one prior ALK inhibitor at the  IASLC 16th World Conference on Lung Cancer in Denver, CO. Patients (n = 6) received AUY-922 (70 mg/m2, iv, qw) until disease progression, unacceptable toxicity or death. No objective responses were observed. The disease control rate and median progression free survival was 50% and 1.43 months, respectively [&lt;ulink linkID="1693862" linkType="Reference"&gt;1693862&lt;/ulink&gt;]&lt;/para&gt;&lt;para&gt;In October 2014, an open-label, multiple arm,  non-randomized, parallel assignment, phase II trial (&lt;ulink linkID="214309" linkType="Protocol"&gt;NCT02276027&lt;/ulink&gt;; CINC280X2205) was planned to be initiated in China, in January 2015, to evaluate the anti-tumor activity of the drug in combination with &lt;ulink linkID="65353" linkType="Drug"&gt;BYL-719&lt;/ulink&gt;, &lt;ulink linkID="59953" linkType="Drug"&gt;INC-280&lt;/ulink&gt;, &lt;ulink linkID="69858" linkType="Drug"&gt;LDK-378&lt;/ulink&gt; and &lt;ulink linkID="55305" linkType="Drug"&gt;MEK-162&lt;/ulink&gt;, in  patients (expected n = 115) with adenocarcinoma lung cancer. At that time, the study was expected to complete by October 2017; by March 2015, the study was initiated in China  [&lt;ulink linkID="1615536" linkType="Reference"&gt;1615536&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2010, a non-randomized, open-label, phase II study (&lt;ulink linkID="66457" linkType="Protocol"&gt;NCT01124864&lt;/ulink&gt;; CAUY922A2206; EudraCT 2010-020116-11) was initiated in the US in patients with advanced NSCLC (expected n = 90)  to assess the efficacy of luminespib [&lt;ulink linkID="1145478" linkType="Reference"&gt;1145478&lt;/ulink&gt;]. In June 2012,    interim data from the trial were presented at the 48th ASCO meeting in Chicago, IL.  In the study, patients (n = 121) received luminespib (70 mg/m2) as a 1-h infusion, qw.   Of the  evaluable patients, partial response (PR) was observed in 17 patients,   stable disease was observed in 41  patients and progressive disease was observed in 56 patients.  At that time, the study had been  discontinued by 89% of patients due to disease progression  [&lt;ulink linkID="1299504" linkType="Reference"&gt;1299504&lt;/ulink&gt;]. In September 2012, further data were presented at the  37th European Society for Medical Oncology Congress in Vienna, Austria.   In EGFR-mutant patients (n = 35), the objective response rate (ORR; including PR) was 20%, and disease control rate (DCR; complete response/partial response or stable disease) was 57% and the rate of progression-free survival (PFS) at 18 weeks was 35.2%. In EGFR-mutant patients with an EGFR tyrosine kinase inhibitor as part of their last regiment (n = 19), the ORR, DCR and the rate of PFS at 18 weeks were 26, 68 and 46.6%, respectively. In Alk+ stratum patients (n = 22), the ORR, DCR and the rate of PFS at 18 weeks were 32, 59 and 35.8%, respectively. Furthermore, in Alk+ patients who were naive to crizotinib (n = 8), the ORR, DCR and the rate of PFS at 18 weeks were 50, 100 and 62.5%, respectively  [&lt;ulink linkID="1325956" linkType="Reference"&gt;1325956&lt;/ulink&gt;]. In October 2013, subgroup analysis data from 66 patients with an EGFR mutation were presented at the 15th World Conference on Lung Cancer in Sydney, Australia.   Overall, 12 patients with an EGFR mutation had partial response, including three unconfirmed partial responses, 33 had stable disease and 21 had progressive disease. The median PFS duration and 18-week PFS rate was approximately 3 months and 36.2%, respectively [&lt;ulink linkID="1491215" linkType="Reference"&gt;1491215&lt;/ulink&gt;]. By April 2015, the study had been completed in 152 patients in the US, Canada, Europe, Turkey, Singapore and Korea   [&lt;ulink linkID="1145478" linkType="Reference"&gt;1145478&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2015, clinical data were presented from a phase Ib, dose-escalation (3 x 3 design), three-cohort study (&lt;ulink linkID="108338" linkType="Protocol"&gt;NCT01784640&lt;/ulink&gt;) in previously treated metastatic, non-squamous NSCLC patients at the IASLC 16th World Conference on Lung Cancer in Denver, CO. Patients received AUY-922 (40, 55 and 70 mg/m2, qw, in cohorts 1, 2 and 3, respectively) plus &lt;ulink linkID="3536" linkType="Drug"&gt;pemetrexed&lt;/ulink&gt; (500 mg/m2, q3w). At that time, enrollment in cohort 3 was stopped due to DLTs. Cohort 2 was in expansion and an additional 15 patients were being enrolled at that dose. The primary endpoint was safety and tolerability of AUY-922 [&lt;ulink linkID="1693647" linkType="Reference"&gt;1693647&lt;/ulink&gt;]. In September 2018, further clinical data were presented at the 19th IASLC World Conference on Lung Cancer in Toronto, Canada. In the 70 mg/m2 cohort, two grade 3 DLTs were observed including thrombocytopenia and supraventricular tachycardia.  MTD was determined to be 55 mg/m2 with pemetrexed. At the MTD, 71% of patients needed a dose reduction. Common drug-related adverse events (DRAEs; primary endpoint) included ocular toxicity or visual disturbances (70%), fatigue (46%), diarrhea (38%), anemia (38%), anorexia (31%) and nausea (23%). Grade 4 to 5 events were not observed. Cmax of AUY-922 was related to increased grade 2 DRAEs (rs = 0.74; p &amp;lt; 0.01) The best response observed was partial response in a single patient for 20 months, prior to expiration of all AUY-922 [&lt;ulink linkID="2080766" linkType="Reference"&gt;2080766&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2013, an open-label, dose-escalation, single-group assignment, phase Ib trial (&lt;ulink linkID="105454" linkType="Protocol"&gt;NCT01772797&lt;/ulink&gt;; CLDK378X2102, 2012-004632-29) was initiated in patients (expected n = 65) with ALK-rearranged NSCLC to evaluate safety, tolerability, pharmacokinetics and anti-tumor activity of the combination of &lt;ulink linkID="69858" linkType="Drug"&gt;LDK-378&lt;/ulink&gt; and luminespib in the US and Singapore. At that time, the trial was expected to complete in May 2015. Reecruitment was planned to be initiated in Spain, Italy and Australia. In July 2013,  the trial was initiated in patients (expected n=22) in patients with NSCLC. In December 2015, the trial was ongoing but not recruiting patients. At that time, the trial was expected to be completed in March 2017 [&lt;ulink linkID="1466373" linkType="Reference"&gt;1466373&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2009, Novartis presented results from a phase I NSCLC trial in Japan. A total of eight patients at 54 or 70 mg of luminespib had PET partial responses, including 3/3 with NSCLC. The MTD had been defined   and the trial was ongoing at that time [&lt;ulink linkID="1065920" linkType="Reference"&gt;1065920&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Gastric cancer&lt;/subtitle&gt;In December 2011, a non-randomized, open-label, phase II study (&lt;ulink linkID="79604" linkType="Protocol"&gt;NCT01404650&lt;/ulink&gt;; SCRI GI 148) was initiated in patients with refractory gastrointestinal stromal tumor (expected n = 34) in the US, to assess the safety and efficacy of luminespib. At that time, the study was scheduled to  complete in March 2013 [&lt;ulink linkID="1235413" linkType="Reference"&gt;1235413&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2011, an open-label, single-arm, multi-center phase II study (&lt;ulink linkID="79541" linkType="Protocol"&gt;NCT01402401&lt;/ulink&gt;) was initiated to evaluate the efficacy and safety of luminespib in combination with &lt;ulink linkID="6386" linkType="Drug"&gt;trastuzumab&lt;/ulink&gt; standard therapy as second-line treatment in patients with HER2-positive advanced gastric cancer (expected n = 48). At that time, the study was estimated to be complete in May 2013 [&lt;ulink linkID="1285105" linkType="Reference"&gt;1285105&lt;/ulink&gt;], [&lt;ulink linkID="1275518" linkType="Reference"&gt;1275518&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2010, a multinational, randomized, open-label, single-group, phase II study (&lt;ulink linkID="64737" linkType="Protocol"&gt;NCT01084330&lt;/ulink&gt;) began to determine the efficacy of luminespib compared with &lt;ulink linkID="2953" linkType="Drug"&gt;docetaxel&lt;/ulink&gt; or &lt;ulink linkID="2871" linkType="Drug"&gt;irinotecan&lt;/ulink&gt; for the second-line treatment of  patients with gastric cancer (expected n = 120) [&lt;ulink linkID="1086229" linkType="Reference"&gt;1086229&lt;/ulink&gt;]. In June 2012, clinical data were presented at the 14th World Congress on Gastrointestinal Cancer in Barcelona, Spain. By that time, 72 patients had been enrolled. The drug showed an acceptable safety profile  with fewer grade 3 or 4 adverse events than docetaxel or irinotecan. Efficacy data were to be presented at a later date [&lt;ulink linkID="1304882" linkType="Reference"&gt;1304882&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2012, a multicenter, non-randomized, open-label, single-group, phase I study (&lt;ulink linkID="88170" linkType="Protocol"&gt;NCT01613950&lt;/ulink&gt;; CBYL719X2103; 2011-005978-40) was planned to assess the safety of &lt;ulink linkID="65353" linkType="Drug"&gt;BYL-719&lt;/ulink&gt; in combination with luminespib in patients with advanced or metastatic gastric cancer with either a PIK3CA mutation or HER2 amplification (expected n = 41). The primary endpoint was the incidence DLTs. An IND was approved in July 2012 and the study was expected to begin in September 2012 and complete in March 2014 [&lt;ulink linkID="1302577" linkType="Reference"&gt;1302577&lt;/ulink&gt;], [&lt;ulink linkID="1338794" linkType="Reference"&gt;1338794&lt;/ulink&gt;]. By  May 2013, the trial had been initiated [&lt;ulink linkID="1302577" linkType="Reference"&gt;1302577&lt;/ulink&gt;]. In September 2014, the trial was completed [&lt;ulink linkID="1302577" linkType="Reference"&gt;1302577&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Breast cancer&lt;/subtitle&gt;In June 2011, data were presented from an ongoing phase II part of a study in patients (n = 10) with HER-2+ or estrogen receptor-positive metastatic breast cancer at the 47th ASCO meeting in Chicago, IL.  The median maximum increase of HSP70  levels was   6.4-fold. A decrease of approximately 45 and 80% was observed in two HER-2+ patients, who remained on study for &amp;gt; 5 cycles;  partial metabolic responses were observed  in both of the patients and a confirmed partial response was observed in one of the patients  [&lt;ulink linkID="1194119" linkType="Reference"&gt;1194119&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2010, a multinational, non-randomized, open label, single-group, phase II study (&lt;ulink linkID="73621" linkType="Protocol"&gt;NCT01271920&lt;/ulink&gt;; CAUY922A2109; EUDRACT 2009-015628-27) began, to assess the efficacy of luminespib in combination with &lt;ulink linkID="6386" linkType="Drug"&gt;trastuzumab&lt;/ulink&gt; in patients with trastuzumab-refractory locally advanced or metastatic HER-2+ breast cancer (expected n = 55). The primary endpoints were MTD and overall response rate [&lt;ulink linkID="1171440" linkType="Reference"&gt;1171440&lt;/ulink&gt;]. In June 2012,  interim clinical data were presented at the 48th ASCO meeting in Chicago, IL.    In the study, patients (n = 42)  received luminespib (70 mg/m2, iv infusion, qw) plus trastuzumab (2 mg/kg). The combination was shown to be well tolerated.  In the phase II portion of the study, 7  of 31 evaluable patients   had a   partial response, 16 had stable disease, 7 had progressive disease and 1 patient had unknown status. By April 2012, 74% of patients had discontinued treatment, mainly due to disease progression [&lt;ulink linkID="1299504" linkType="Reference"&gt;1299504&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Colorectal cancer&lt;/subtitle&gt;In February 2011, a non-randomized, open label, active controlled, single-group, phase I study (&lt;ulink linkID="74724" linkType="Protocol"&gt;NCT01294826&lt;/ulink&gt;; CAUY922AUS06T) began in the US, to assess the safety and efficacy of luminespib in combination with &lt;ulink linkID="10388" linkType="Drug"&gt;cetuximab&lt;/ulink&gt; in patients with KRAS wild-type metastatic colorectal cancer (expected n = 18). The primary endpoint was the incidence of DLTs. The study was expected to complete in August 2013 [&lt;ulink linkID="1171417" linkType="Reference"&gt;1171417&lt;/ulink&gt;]. In June 2015, clinical data were presented at the 51st ASCO meeting in Chicago, IL.  Partial response and stable disease was observed in one and four patients, respectively. The disease control rate was 31.3%. The median overall survival and median time to progression was 37.2 and 7.9 week, respectively [&lt;ulink linkID="1663462" linkType="Reference"&gt;1663462&lt;/ulink&gt;]&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Solid tumors&lt;/subtitle&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;By March 2010, a phase II proof-of-concept trial of the drug in solid tumors had commenced [&lt;ulink linkID="1082033" linkType="Reference"&gt;1082033&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;In July 2007, Novartis initiated a phase I/II  trial (&lt;ulink linkID="26180" linkType="Protocol"&gt;NCT00526045&lt;/ulink&gt;; CAUY922A2101) to evaluate  iv luminespib in adults with advanced solid malignancies, including breast cancer. The phase I dose-escalation, multicenter, open-label study would recruit 125 patients to receive a once-weekly schedule to determine the MTD. The trial would be followed  with a phase II expansion study to examine efficacy in  HER2+ or ER+ locally advanced or metastatic breast cancer [&lt;ulink linkID="830877" linkType="Reference"&gt;830877&lt;/ulink&gt;]. In May 2009, data from the ongoing trial were presented at the 45th ASCO meeting in Orlando, FL. Atrial flutter (22 mg/m2), anorexia (40 mg/m2), diarrhea (40 mg/m2) and asthenia (54 mg/m2) were considered to be DLTs. At the time of presentation, no complete or partial responses had been observed. The terminal half-life of luminespib was approximately 60 h. At that time, the 54-mg/m2 cohort was being expanded to assess safety at this dose level. In 50 evaluable subjects, the average baseline level of Hsp 70 in PBMCs was 64.8 ng/mg of protein, blood Cmax increased dose-dependently and a dose-proportional increase in AUC was observed; Hsp 70 induction in PBMCs correlated with luminespib blood AUC at 40 mg/m2 or lower [&lt;ulink linkID="1006620" linkType="Reference"&gt;1006620&lt;/ulink&gt;], [&lt;ulink linkID="1006648" linkType="Reference"&gt;1006648&lt;/ulink&gt;], [&lt;ulink linkID="1014143" linkType="Reference"&gt;1014143&lt;/ulink&gt;].   In June 2010, further data were presented at the 46th ASCO meeting in Chicago, IL. Drug MTD was 70 mg/m2 qw iv. Adverse events up to this dose were manageable and reversible. No objective response was reported at that time. Stable disease as best overall response was seen in 18% of patients. Terminal half-life was 120 h at 70 mg/m2 [&lt;ulink linkID="1103922" linkType="Reference"&gt;1103922&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In September 2013, Novartis filed a clinical trial application in China, presumed to be for solid tumor [&lt;ulink linkID="1474618" linkType="Reference"&gt;1474618&lt;/ulink&gt;], [&lt;ulink linkID="1473712" linkType="Reference"&gt;1473712&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt; In January 2013, clinical data were presented at ASCO's Gastrointestinal Cancer Symposium in San Francisco, CA. In a phase I study (&lt;ulink linkID="71565" linkType="Protocol"&gt;NCT01226732&lt;/ulink&gt;) in patients (n = 23) with refractory solid tumors, treatment with luminespib in combination with &lt;ulink linkID="12205" linkType="Drug"&gt;capecitabine&lt;/ulink&gt; resulted in  three unconfirmed partial responses,  one confirmed partial response and eight incidents of stable disease [&lt;ulink linkID="1363590" linkType="Reference"&gt;1363590&lt;/ulink&gt;]. In June 2013, further data from 23 patients were presented at the 49th ASCO meeting in Chicago, IL. Combination therapy with luminespib (22 to 70 mg/m2, iv on days 1, 8 and 15) and capecitabine (1000 or 1250 mg/m2, po, bid on days 1 to 14 in 3-week cycles) was well tolerated. Partial response was seen in four patients [&lt;ulink linkID="1427103" linkType="Reference"&gt;1427103&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2012, clinical data were presented at the 48th ASCO meeting in Chicago, IL. In a phase I dose-escalation study of  luminespib   in combination with    &lt;ulink linkID="11961" linkType="Drug"&gt;erlotinib&lt;/ulink&gt;,  patients  (n = 15), with EGFR-mutant lung cancer and    acquired resistance  to EGFR tyrosine kinase  inhibitors received luminespib (25, 37.5, 55  or  70 mg/m2, iv infusion, qw) and erlotinib (75 or 150 mg, po). The combination was well tolerated.  One patient had a partial response,  2  patients had stable disease for longer than 6 months    and 11 patients     discontinued treatment.  At that time, 3 additional patients were being recruited to confirm the MTD (AUY-922 70 mg/m2, iv infusion, qw +   erlotinib  75 or 150 mg, po) [&lt;ulink linkID="1299662" linkType="Reference"&gt;1299662&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;In September 2007, the companies disclosed that  this program had entered phase I trials, but did not disclose the compound [&lt;ulink linkID="827088" linkType="Reference"&gt;827088&lt;/ulink&gt;]; in October 2007 it was confirmed that luminespib had entered phase I trials in patients with solid malignancies  [&lt;ulink linkID="844742" linkType="Reference"&gt;844742&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Multiple myeloma&lt;/subtitle&gt;In July 2008, a three-part phase I/Ib/II study (&lt;ulink linkID="25594" linkType="Protocol"&gt;NCT00708292&lt;/ulink&gt;; CAUY922A2103) began to determine the MTD of iv luminespib alone and in combination with &lt;ulink linkID="15954" linkType="Drug"&gt;bortezomib&lt;/ulink&gt;, with or without dexamethasone, in patients  with multiple myeloma (expected n = 70) [&lt;ulink linkID="925021" linkType="Reference"&gt;925021&lt;/ulink&gt;].   In June 2012,  clinical data from the trial were presented at the 17th EHA Annual Congress in Amsterdam, the Netherlands. In the study, three of five patients that received    luminespib   in combination  with bortezomib experienced  grade 3 DLTs   and so no further dose escalation was performed and the study was discontinued [&lt;ulink linkID="1302070" linkType="Reference"&gt;1302070&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Myelofibrosis&lt;/subtitle&gt;In August 2012, an open-label, single-group, phase II study (&lt;ulink linkID="90298" linkType="Protocol"&gt;NCT01668173&lt;/ulink&gt;; 12-076) began in the US to assess the safety and efficacy of luminespib in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (Post-PV MF), post-essential thrombocythemia myelofibrosis (Post-ET MF) and refractory PV/ET (expected n = 25). The primary endpoint was overall response rate. The study was expected to complete in August 2014 [&lt;ulink linkID="1325783" linkType="Reference"&gt;1325783&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In December 2013, preclinical data were presented at the 55th ASH Meeting in New Orleans, LA.  In KK1, KOB, SO4, ST1, LM-Y1 and HuT102 cell lines, sub G1/G1 phase arrest and apoptosis were induced by NVP-AUY9-22. In C.B-17/Icr-SCID mice, administration of NVP-AUY9-22 (12.5, 18.0 and 30.0 mg/kg) significantly impaired the growth of tumor. Down regulation of PIM kinases was induced NVP-AUY9-22. At that time, phase I/II trials of NVP-AUY9-22 were ongoing in patients with advanced solid tumors and hematological malignancies [&lt;ulink linkID="1503133" linkType="Reference"&gt;1503133&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In November 2013, preclinical data were presented at the NCRI Cancer Conference in Liverpool, UK. In ex vivo samples from patients treated with luminespib, the drug significantly induced Hsp70 and transiently induced Hsp90a in PBMCs [&lt;ulink linkID="1499041" linkType="Reference"&gt;1499041&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2012, data were presented at the 244th ACS meeting in Philadelphia, PA. Of the 4-aryl-5-cyanopyrrolo [2, 3-d] pyrimidines  tested, one compound showed excellent antiproliferative activity with GI50 values of 34, 131 and 34 nM in BT474, HCT116 and MDA-MB-468 cells, respectively. In Balb-C-mouse, this compound (5 mg/kg) showed moderate exposure in plasma with reasonalble half-life (&amp;gt; 1 h) and was found to be bioavailable when administered po [&lt;ulink linkID="1315398" linkType="Reference"&gt;1315398&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2012, preclinical data were presented at the 103rd AACR meeting in Chicago, IL. In vitro, in breast and gastric cancer cell lines, luminespib demonstrated potent activity in nanomolar range. In HER2-amplified breast (BT474 and SKBR3) and gastric cancer (N87 and OE19) cell lines, the combination of luminespib and &lt;ulink linkID="6386" linkType="Drug"&gt;trastuzumab&lt;/ulink&gt; showed significant synergy in all cell lines. In HER2-amplified trastuzumab-conditioned breast and gastric cancer cell lines, the combination of luminespib and trastuzumab exhibited synergy and decreased phosphorylated-AKT, although to a lesser extent than in the corresponding parental cell lines. With both single-agent luminespib and the combination, levels of Hsp-70 were elevated to a similar degree, but not with single-agent trastuzumab. In mice bearing NCI-N87 trastuzumab-conditioned xenografts, single-agent luminespib caused some statistically significant tumor regression; however, the combination of luminespib and trastuzumab showed near complete tumor regression by day 15 [&lt;ulink linkID="1275518" linkType="Reference"&gt;1275518&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2011, preclinical data were presented at the 53rd ASH meeting in San Diego, CA from studies against B-cell acute lymphoblastic leukemia (B-ALL) with rearrangements of the cytokine receptor subunit CRLF2. The MHH-CALL4 and MUTZ-5 cell lines were 50- to 1000-fold more sensitive to luminespib compared with  several JAK inhibitors, with GI50 values ranging from 25 to 26 nM. In NOD mice with established primary with B-ALL xenografts, luminespib (50 mg/kg three times a week) did not completely efface B-ALL but overall survival was prolonged [&lt;ulink linkID="1244967" linkType="Reference"&gt;1244967&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2011, preclinical data were presented at the 102nd AACR meeting in Orlando, FL. Across a panel of 24 different NSCLC cell lines containing KRAS, BRAF or EGFR mutations, only the H1395 and Calu3 cell lines were resistant to luminespib, and, among the sensitive cell lines, the mean IC50 value for luminespib was 18.7 nM [&lt;ulink linkID="1174939" linkType="Reference"&gt;1174939&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2010, preclinical data were presented at the 101st AACR meeting in Washington DC. In vitro results showed that luminespib dose-dependently reduced pancreatic cancer cell proliferation and blocked STAT3, Akt, Erk, and FAK activation.    Luminespib also significantly reduced VEGF-A-mediated EC migration, suggesting a potential antiangiogenic effect. In sc xenograft models, treatment with luminespib significantly reduced tumor growth rates of pancreatic cancer cells, and reduced vascularization [&lt;ulink linkID="1089355" linkType="Reference"&gt;1089355&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;In April 2009, preclinical data were presented at the 100th AACR meeting in Denver, CO. In vivo, luminespib (iv, 25 or 50 mg/kg) significantly reduced tumor size   in a dose dependent manner. Also, a single iv dose  of 75 mg/kg  induced HSP70 expression, which was shown in xenografts to be specific to HSP90 inhibitors only [&lt;ulink linkID="997858" linkType="Reference"&gt;997858&lt;/ulink&gt;]. Further preclinical data presented at this conference demonstrated that luminespib and  another inhibitor, &lt;ulink linkID="63039" linkType="Drug"&gt;NVP-BEP-800&lt;/ulink&gt;, efficiently inhibited cell proliferation of Bcr-Abl-positive cell lines which were sensitive or resistant to &lt;ulink linkID="11460" linkType="Drug"&gt;imatinib&lt;/ulink&gt; and NVP-BEP-800 was more potent than luminespib in various Bcr-Abl-positive cells [&lt;ulink linkID="998054" linkType="Reference"&gt;998054&lt;/ulink&gt;]. At the same meeting, data were presented showing that 50 nM luminespib  significantly decreased VEGF excretion  under normoxic and hypoxic conditions. The same dose of the drug also reduced HIF1 alpha under hypoxic conditions [&lt;ulink linkID="998333" linkType="Reference"&gt;998333&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2008, preclinical data were presented at the 99th AACR meeting in San Diego, CA. Data presented by the University of Wuerzburg, in collaboration with &lt;ulink linkID="23137" linkType="Company"&gt;Novartis&lt;/ulink&gt;, showed the anti-myeloma activity and the pharmacodynamic properties of luminespib in AMO-1, INA-6, KMS-12-BM, MM.1s, MOLP-8, OPM-2, RMPI-8226, and the U266 MM cell lines with EC50 values of 10, 11, 19, 21, 10, 19, 20, and 24 nM, respectively [&lt;ulink linkID="896424" linkType="Reference"&gt;896424&lt;/ulink&gt;]. The &lt;ulink linkID="22181" linkType="Company"&gt;Medical College of Georgia&lt;/ulink&gt;, in collaboration with  &lt;ulink linkID="26879" linkType="Company"&gt;Novartis&lt;/ulink&gt; also presented data on the combined treatment of luminespib with &lt;ulink linkID="54226" linkType="Drug"&gt;panobinostat&lt;/ulink&gt;. Data showed that the combination displayed synergistic antileukemia activity against human AML and CML cells [&lt;ulink linkID="896423" linkType="Reference"&gt;896423&lt;/ulink&gt;]. In December 2008, similar preclinical data were presented at the 50th ASH meeting in San Francisco, CA. Luminespib attenuated signalling in human myeloproliferative disorder cells when in combination with &lt;ulink linkID="54226" linkType="Drug"&gt;panobinostat&lt;/ulink&gt; and enhanced the activity of &lt;ulink linkID="56516" linkType="Drug"&gt;TG-101209&lt;/ulink&gt; [&lt;ulink linkID="968122" linkType="Reference"&gt;968122&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2007,  data were presented at the 49th ASH meeting in Atlanta, GA. Luminespib was found to time- and dose-dependently affect anti- (multiple myeloma) MM activity. The anti-MM activity was rapid with MM cells being committed to cell death within 16 h of exposure to only 25 nM of luminespib.  Luminespib also overcame the protective effects  conferred to MM cells by exogenous IL-6 and IGF-1. Treatment of MM-1S cells with luminespib caused early G2/M arrest followed by an increase in cell death, and caspase-3 and -8 cleavage. No synergy was observed when used in combination with conventional and novel anti-MM agents, and no antagonism was observed with any of the combinations [&lt;ulink linkID="858363" linkType="Reference"&gt;858363&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2007, preclinical data were presented at the 19th AACR-NCI-EORTC International Conference in San Francisco, CA. In vitro, luminespib (VER-52296)  showed high tumor exposure and levels in HCT-116 cells, with a GI50 value of 85 nM [&lt;ulink linkID="845043" linkType="Reference"&gt;845043&lt;/ulink&gt;].    In vitro, luminespib  inhibited human endothelial cell proliferation with GI50 values of 3.9 and 2.5 nM in HUVEC and HDMEC cells, respectively and  inhibited Erbb2 signaling and localization in human breast cancer cells. In vivo,  daily dosing of luminespib (50 mg/kg ip or iv) was administered to athymic mice bearing established human tumor xenografts. Luminespib  inhibited the growth and metastasis of WM266.4 melanoma xenografts, U87MG glioblastoma xenografts, A2780 ovarian carcinoma,  PC3LN3 prostate carcinoma, and BT474 breast carcinoma  with T/C values of 31, 7, 10.5, 37, and 21%, respectively [&lt;ulink linkID="845008" linkType="Reference"&gt;845008&lt;/ulink&gt;]. In a dosing pharmacokinetic study in tumor bearing mice, luminespib  demonstrated high tumor uptake and retention compared with plasma when dosed ip or iv. Luminespib exhibited high potency against the Hsp90 ATPase site with a Ki of 9 nM in an FP assay and significant in vitro growth inhibition (in the range 2 to 25 nM) against a panel of human cancer cell lines. Luminespib  exhibited efficacy in a range of subcutaneous and orthotopic xenograft models covering major cancer types (including HCT116 colon, U87MG glioblastoma, PC3 prostate, BT474 breast and WM266 melanoma) [&lt;ulink linkID="845001" linkType="Reference"&gt;845001&lt;/ulink&gt;].  At that time, it was reported  that  luminespib had entered phase I clinical trials in July 2007  [&lt;ulink linkID="844742" linkType="Reference"&gt;844742&lt;/ulink&gt;]. In April 2008, similar data were presented at the 19th Medicinal Chemistry in Eastern England Symposium in Hatfield, UK [&lt;ulink linkID="902833" linkType="Reference"&gt;902833&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2007, preclinical data on the pyrazole VER-49009 and isoxazole VER-50589  were presented at the 98th AACR meeting in Los Angeles, CA. The compounds exhibited up to 40-fold more potency than CCT-018159 against Hsp 90 and human cancer cells. VER-49009 and VER-50589 had IC50 values of 167 ± 9 nM and 143 ± 23 nM, respectively, in an ATPase enzyme assay and 47 ± 9 nM and 21 ± 4 nM, respectively, in a fluorescent binding assay. Across a panel of human cancer cell lines, mean cellular GI50 values  were   644.1 and 71.9 nM for VER-49009 and VER-50589, respectively. The cellular sensitivity of both inhibitors was independent of NQO1/DT-diaphorase and P-glycoprotein expression. Both compounds caused an induction of Hsp 70 and Hsp 27, downregulation of oncogenic client proteins, and reduction of phospho-ERK1/2 and phospho-AKT levels. In HCT116 human colon cancer xenografts, VER-50589 accumulated at tumor levels above cellular GI50 for 24 h post dosing, with doses of 100 mg/kg qd yielding 30% growth inhibition, as well as induction of Hsp 70 and depletion of ERBB2. VER-50589 also exhibited superior pharmacodynamics to VER-49009 in an orthotopic ovarian carcinoma model [&lt;ulink linkID="778281" linkType="Reference"&gt;778281&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2007, preclinical data on CCT-018159 were published. CCT-018159 inhibited human Hsp 90 with potency comparable with &lt;ulink linkID="16376" linkType="Drug"&gt;17-AAG&lt;/ulink&gt;. The compound displayed similar binding properties to &lt;ulink linkID="27973" linkType="Drug"&gt;radicicol&lt;/ulink&gt; and a mean cellular GI50 value  of 5.3 microg/l in melanoma cell lines.  The drug caused cell cytostasis and induced apoptosis; the antitumor activity was independent of NQO1/DT-diaphorase and P-glycoprotein expression [&lt;ulink linkID="777735" linkType="Reference"&gt;777735&lt;/ulink&gt;], [&lt;ulink linkID="777720" linkType="Reference"&gt;777720&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Earlier in March 2007, preclinical data were presented at the Fragments 2007 meeting in Cambridge, UK [&lt;ulink linkID="775402" linkType="Reference"&gt;775402&lt;/ulink&gt;] and at the 3rd Anglo-Swedish Medicinal Chemistry Symposium in Are, Sweden [&lt;ulink linkID="777963" linkType="Reference"&gt;777963&lt;/ulink&gt;]. Optimization of CCT-018159 led to VER-510747 (IC50 = 21 nM), which  was further modified to provide the initial development candidate (structure not disclosed). The resulting compound had   IC50 values of 83 and 320 nM in HCT116 and DU145 cells, respectively [&lt;ulink linkID="775402" linkType="Reference"&gt;775402&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2006,  data were presented at the 40th SMR conference in London, UK. Further modification, directed by structural chemistry, added an amide group to the 5-position, leading to a significant increase in activity from an IC50 value of 8 microM to 80 nM with VER-49009. A bioisosteric replacement of oxazole for pyrazole produced VER-50589 (IC50 = 28 nM), which displayed a 5- to 10-fold increase in cellular potency. At that time, intravenous and oral preclinical development candidates had  been selected and were progressing [&lt;ulink linkID="752487" linkType="Reference"&gt;752487&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2006, Vernalis published data showing that a 10-fold loss in activity resulted from the removal of Hsp 90's lipophilic substituents at the 4-position of the resorcinol. Little effect was observed, however, when the protein's aryl ring at the 4-position of the pyrazole was altered [&lt;ulink linkID="776613" linkType="Reference"&gt;776613&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By July 2005, 1-(2-phenol)-2-naphthols had been identified as Hsp 90 inhibitors.  One compound had an IC50 value of 0.7 microM in a fluorescent polarization assay, and caused cell growth inhibition at 29 microM [&lt;ulink linkID="668258" linkType="Reference"&gt;668258&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By October 2004, data were published on dihydroxyphenylpyrazoles as a unique class of reversible Hsp90 inhibitors. The crystal structure of G-3130 and G-3129 complexed with the N-terminal ATP binding domain of human Hsp 90alpha were also reported. G3130 showed cellular activities (in Her-2 degradation and activation of Hsp 70 promoter) consistent with the inhibition of cellular Hsp 90 functions [&lt;ulink linkID="654763" linkType="Reference"&gt;654763&lt;/ulink&gt;]. By June 2005, further data were reported on a  series of 3-(5-chloro-2,4-dihydroxyphenyl)-pyrazole-4-carboxamides, with one compound having an IC50 value of 0.258 microM in a fluorescent polarization assay, and  a GI50 value of 11.6 microM [&lt;ulink linkID="668280" linkType="Reference"&gt;668280&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2004, preclinical data on CCT-018159   and its analogs were presented at the 16th EORTC-NCI-AACR meeting in Geneva, Switzerland. The compound had ATPase and cellular IC50 values of 6.4 and 4 microM. The derivatives of this compound had a 4 to 30-fold increase in enzyme potency and up to a 10-fold improvement in cellular potency in a range of tumor types including colon and melanoma cell lines. Apoptosis was demonstrated in HCT-116 treated colon cancer cells. Pharmacokinetic properties of these analogs are promising  and they were more soluble than 17-AAG [&lt;ulink linkID="563905" linkType="Reference"&gt;563905&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2004, data were presented at the 95th AACR meeting in Orlando, FL. Improved activity and potency was observed against the yeast and human recombinant Hsp 90 ATPase activity with a series of CCT-018159 analogs. Anticancer activity in cell culture was demonstrated in a range of tumor types, including HCT116 colon carcinoma and various melanoma cell lines. Cell-line dependent G1 and G2M arrest and apoptosis was noted, and activity was retained in a P-glycoprotein positive cell line made resistant to doxorubicin and also in cells made resistant to platinum agents [&lt;ulink linkID="530956" linkType="reference"&gt;530956&lt;/ulink&gt;]. In August 2004, similar preclinical data on CCT-018159 and its analogs were presented at the 18th International Symposium on Medicinal Chemistry in Copenhagen, Denmark and Malmo, Sweden [&lt;ulink linkID="552536" linkType="Reference"&gt;552536&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;By March 2004, VER-49009 had been identified as the most potent compound in the series  [&lt;ulink linkID="530956" linkType="reference"&gt;530956&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In November 2003, preclinical data on Hsp 90 inhibitors were presented at the 15th AACR-NCI-EORTC meeting in Boston, MA. RiboTargets determined the structure of the N terminal domain of Hsp 90alpha (Nt-HSP90) in complex with the inhibitor PU3, and designed analogs of PU3 that showed enhanced potency. RiboTargets also determined the first structure of the homolog Nt-HSP 90beta in complex with PU3. In a further presentation, RiboTargets described its modifications of &lt;ulink linkID="39169" linkType="Drug"&gt;CCT-018159&lt;/ulink&gt; to produce molecules with improvements that inhibited Hsp 90 with a Ki value in the sub-micromolar range. In addition, CCT-018159 was shown to have similar effects to &lt;ulink linkID="16376" linkType="Drug"&gt;17-AAG&lt;/ulink&gt; in relation to client protein depletion, cell cycle arrest and apoptosis in the A2780 ovarian tumor, and its molecular signature using gene expression profiling was found to be similar to 17-AAG and radicicol. In another presentation at the meeting, pharmacokinetic and metabolic properties of CCT-018159 and four structural analogs (&lt;ulink linkID="39169-X4" linkType="Compound"&gt;CCT-066950&lt;/ulink&gt;, &lt;ulink linkID="39169-X5" linkType="Compound"&gt;CCT-066952&lt;/ulink&gt;, &lt;ulink linkID="39169" linkType="Drug"&gt;CCT-0669963&lt;/ulink&gt; and &lt;ulink linkID="39169-X6" linkType="Compound"&gt;CCT-066965&lt;/ulink&gt;) were assessed. The studies showed that the pharmacokinetics of CCT-018159 and its analogs were complex and that cassette dosing was the best way to assess them. As of November 2003, this method was being applied to identify compounds with more optimized pharmacokinetic properties during structural analog synthesis [&lt;ulink linkID="513709" linkType="reference"&gt;513709&lt;/ulink&gt;], [&lt;ulink linkID="513711" linkType="reference"&gt;513711&lt;/ulink&gt;], [&lt;ulink linkID="513776" linkType="reference"&gt;513776&lt;/ulink&gt;], [&lt;ulink linkID="515680" linkType="reference"&gt;515680&lt;/ulink&gt;]. Mechanisms of action of CCT-018159 and 17AAG in malignant melanoma cell lines were also discussed in November 2003, at the 15th AACR-NCI-EORTC meeting [&lt;ulink linkID="513781" linkType="reference"&gt;513781&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2003, preclinical data on CCT-018159, a small molecule inhibitor of the ATPase activity of Hsp 90, were presented at the 94th AACR Meeting, Washington, DC. CCT-018159 (IC50 = 8.9 microM) was shown to inhibit the growth of HT29 and HCT116 cells. Hsp 70 was induced 2- to 3-fold following exposure to CCT-018159 (10 microM) for 24 to 48 h [&lt;ulink linkID="497035" linkType="reference"&gt;497035&lt;/ulink&gt;]. At the same meeting, Ribotargets disclosed its proprietary virtual screening program rDock had been used to identify compounds similar to CCT-018159 that inhibit ATPase activity in Hsp 90. In addition, a streamlined fragment-based approach combining NMR and crystallography had identified novel structural moieties able to bind to the ATP binding pocket. The initial set of fragments contained chemical structures similar to those found in CCT-018159 and other ATP-binding site inhibitors of Hsp90, such as geldanamycin, ADP-PNP and radicicol. At that time, the company aimed to design and develop improved compounds with appropriate drug-like properties as inhibitors [&lt;ulink linkID="485523" linkType="reference"&gt;485523&lt;/ulink&gt;], [&lt;ulink linkID="498726" linkType="reference"&gt;498726&lt;/ulink&gt;], [&lt;ulink linkID="497035" linkType="reference"&gt;497035&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In May 2003, at the Protein Kinases and GPCRs seminar, organized by BioFocus in Cambridge, UK, it was reported that by using a mixture of in silico approaches and HTS methods, small-molecule inhibitors of Hsp90 based on an aminopyrimidine nucleus had been identified, which have IC50 values in the 10 microM range; &lt;ulink linkID="39169-X1" linkType="Compound"&gt;PH-3&lt;/ulink&gt; is one such compound [&lt;ulink linkID="490537" linkType="reference"&gt;490537&lt;/ulink&gt;]. In August 2003, similar data were presented at the Drug Discovery Technology conference in Boston, MA. The compound had 2- to 3-fold improved in vivo activity compared to &lt;ulink linkID="16376" linkType="Drug"&gt;17-AAG&lt;/ulink&gt; [&lt;ulink linkID="502877" linkType="reference"&gt;502877&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt; In December 2003, Vernalis formed a research collaboration with the &lt;ulink linkID="23137" linkType="Company"&gt;Novartis&lt;/ulink&gt; Institute for Biomedical Research (NIBR) to investigate targets implicated in a range of cancers [&lt;ulink linkID="517656" linkType="Reference"&gt;517656&lt;/ulink&gt;]. In September 2004, Novartis signed an agreement with Vernalis to provide research funding for Vernalis' Hsp 90 inhibitors program, initially for 3 years. Novartis would be responsible for the preclinical and clinical development and commercialization of any drug candidates resulting from the research [&lt;ulink linkID="559635" linkType="Reference"&gt;559635&lt;/ulink&gt;]. However, in December 2014, Novartis ceased the  development of the drug and reverted all the rights back to Vernalis  [&lt;ulink linkID="1622106" linkType="Reference"&gt;1622106&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In March 2002, originator &lt;ulink linkID="24962" linkType="Company"&gt;RiboTargets&lt;/ulink&gt; (now &lt;ulink linkID="15262" linkType="Company"&gt;Vernalis&lt;/ulink&gt;), &lt;ulink linkID="15935" linkType="Company"&gt;Cancer Research Ventures&lt;/ulink&gt; and &lt;ulink linkID="21072" linkType="Company"&gt;The Institute of Cancer Research&lt;/ulink&gt;, formed a collaboration to identify and develop inhibitors of the Hsp 90 protein family. &lt;ulink linkID="21072" linkType="Company"&gt;The Institute of Cancer Research&lt;/ulink&gt; was to evaluate inhibitors of HSP 90 and provide expertise necessary for drug development. RiboTargets was to provide the chemistry and structure capabilities to identify new compounds [&lt;ulink linkID="446766" linkType="Reference"&gt;446766&lt;/ulink&gt;]. In September 2004, Vernalis licensed exclusive worldwide rights to the Hsp 90 program [&lt;ulink linkID="561601" linkType="Reference"&gt;561601&lt;/ulink&gt;]. Milestone payments to Cancer Research Technology (CRT) and the Institute of Cancer Research were to be made by Vernalis [&lt;ulink linkID="743597" linkType="Reference"&gt;743597&lt;/ulink&gt;], [&lt;ulink linkID="750576" linkType="Reference"&gt;750576&lt;/ulink&gt;].&lt;br&gt;&lt;/br&gt;&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="15262">Vernalis plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="S" sortOrder="6">Suspended</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2015-08-04T00:00:00.000Z</StatusDate><Source id="1683196" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="TR">Turkey</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate>2014-12-19T00:00:00.000Z</StatusDate><Source id="1622106" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate>2014-12-19T00:00:00.000Z</StatusDate><Source id="1622106" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="LB">Lebanon</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="127">Stomach tumor</Indication><StatusDate>2014-12-19T00:00:00.000Z</StatusDate><Source id="1622106" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="725">Solid tumor</Indication><StatusDate>2014-12-19T00:00:00.000Z</StatusDate><Source id="1622106" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="XH">Far East</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="127">Stomach tumor</Indication><StatusDate>2014-12-19T00:00:00.000Z</StatusDate><Source id="1622106" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="989">Colorectal tumor</Indication><StatusDate>2014-12-19T00:00:00.000Z</StatusDate><Source id="1622106" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="1828">Multiple myeloma</Indication><StatusDate>2012-06-16T00:00:00.000Z</StatusDate><Source id="1302070" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="127">Stomach tumor</Indication><StatusDate>2014-12-19T00:00:00.000Z</StatusDate><Source id="1622106" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="SG">Singapore</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="49">Breast tumor</Indication><StatusDate>2014-12-19T00:00:00.000Z</StatusDate><Source id="1622106" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="CN">China</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="725">Solid tumor</Indication><StatusDate>2014-12-19T00:00:00.000Z</StatusDate><Source id="1622106" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="651">Cancer</Indication><StatusDate>2014-12-19T00:00:00.000Z</StatusDate><Source id="1622106" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="CN">China</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="2399">Adenocarcinoma</Indication><StatusDate>2014-12-19T00:00:00.000Z</StatusDate><Source id="1622106" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="SG">Singapore</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate>2014-12-19T00:00:00.000Z</StatusDate><Source id="1622106" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="ES">Spain</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate>2014-12-19T00:00:00.000Z</StatusDate><Source id="1622106" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="127">Stomach tumor</Indication><StatusDate>2014-12-19T00:00:00.000Z</StatusDate><Source id="1622106" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="127">Stomach tumor</Indication><StatusDate>2014-12-19T00:00:00.000Z</StatusDate><Source id="1622106" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate>2014-12-19T00:00:00.000Z</StatusDate><Source id="1622106" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1729">B-cell acute lymphoblastic leukemia</Indication><StatusDate>2014-12-19T00:00:00.000Z</StatusDate><Source id="1622106" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="2436">Myelofibrosis</Indication><StatusDate>2014-12-19T00:00:00.000Z</StatusDate><Source id="1622106" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="ES">Spain</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1828">Multiple myeloma</Indication><StatusDate>2014-12-19T00:00:00.000Z</StatusDate><Source id="1622106" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="SG">Singapore</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1828">Multiple myeloma</Indication><StatusDate>2012-06-16T00:00:00.000Z</StatusDate><Source id="1302070" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="49">Breast tumor</Indication><StatusDate>2014-12-19T00:00:00.000Z</StatusDate><Source id="1622106" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3669">Metastatic pancreas cancer</Indication><StatusDate>2014-12-19T00:00:00.000Z</StatusDate><Source id="1622106" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="203">Lymphoma</Indication><StatusDate>2014-12-19T00:00:00.000Z</StatusDate><Source id="1622106" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3713">Advanced solid tumor</Indication><StatusDate>2014-12-19T00:00:00.000Z</StatusDate><Source id="1622106" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate>2014-12-19T00:00:00.000Z</StatusDate><Source id="1622106" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="TR">Turkey</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="127">Stomach tumor</Indication><StatusDate>2014-12-19T00:00:00.000Z</StatusDate><Source id="1622106" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="127">Stomach tumor</Indication><StatusDate>2014-12-19T00:00:00.000Z</StatusDate><Source id="1622106" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="49">Breast tumor</Indication><StatusDate>2014-12-19T00:00:00.000Z</StatusDate><Source id="1622106" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3205">Gastrointestinal stromal tumor</Indication><StatusDate>2014-12-19T00:00:00.000Z</StatusDate><Source id="1622106" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1828">Multiple myeloma</Indication><StatusDate>2012-06-16T00:00:00.000Z</StatusDate><Source id="1302070" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="IT">Italy</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate>2014-12-19T00:00:00.000Z</StatusDate><Source id="1622106" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate>2014-12-19T00:00:00.000Z</StatusDate><Source id="1622106" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="SG">Singapore</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1828">Multiple myeloma</Indication><StatusDate>2008-07-16T00:00:00.000Z</StatusDate><Source id="925021" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1828">Multiple myeloma</Indication><StatusDate>2008-07-16T00:00:00.000Z</StatusDate><Source id="925021" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1828">Multiple myeloma</Indication><StatusDate>2008-07-16T00:00:00.000Z</StatusDate><Source id="925021" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3669">Metastatic pancreas cancer</Indication><StatusDate>2011-12-01T00:00:00.000Z</StatusDate><Source id="1248265" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="989">Colorectal tumor</Indication><StatusDate>2011-02-08T00:00:00.000Z</StatusDate><Source id="1171417" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2008-12-09T00:00:00.000Z</StatusDate><Source id="1065920" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="SG">Singapore</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate>2013-05-31T00:00:00.000Z</StatusDate><Source id="1466373" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="3713">Advanced solid tumor</Indication><StatusDate>2008-11-30T00:00:00.000Z</StatusDate><Source id="1240025" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3205">Gastrointestinal stromal tumor</Indication><StatusDate>2011-12-13T00:00:00.000Z</StatusDate><Source id="1235413" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate>2010-10-20T00:00:00.000Z</StatusDate><Source id="1145478" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="ES">Spain</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1828">Multiple myeloma</Indication><StatusDate>2008-07-16T00:00:00.000Z</StatusDate><Source id="925021" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="127">Stomach tumor</Indication><StatusDate>2010-04-30T00:00:00.000Z</StatusDate><Source id="1086229" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate>2010-09-30T00:00:00.000Z</StatusDate><Source id="1171440" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="SG">Singapore</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate>2010-09-30T00:00:00.000Z</StatusDate><Source id="1171440" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="TR">Turkey</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="127">Stomach tumor</Indication><StatusDate>2010-04-30T00:00:00.000Z</StatusDate><Source id="1086229" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="127">Stomach tumor</Indication><StatusDate>2010-04-30T00:00:00.000Z</StatusDate><Source id="1086229" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="127">Stomach tumor</Indication><StatusDate>2010-04-30T00:00:00.000Z</StatusDate><Source id="1086229" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="127">Stomach tumor</Indication><StatusDate>2010-04-30T00:00:00.000Z</StatusDate><Source id="1086229" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="XH">Far East</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="127">Stomach tumor</Indication><StatusDate>2010-04-30T00:00:00.000Z</StatusDate><Source id="1086229" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate>2007-07-31T00:00:00.000Z</StatusDate><Source id="830877" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3669">Metastatic pancreas cancer</Indication><StatusDate>2012-09-07T00:00:00.000Z</StatusDate><Source id="1248265" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate>2007-07-31T00:00:00.000Z</StatusDate><Source id="830877" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="LB">Lebanon</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="127">Stomach tumor</Indication><StatusDate>2010-04-30T00:00:00.000Z</StatusDate><Source id="1086229" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2436">Myelofibrosis</Indication><StatusDate>2012-08-13T00:00:00.000Z</StatusDate><Source id="1325783" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate>2013-05-31T00:00:00.000Z</StatusDate><Source id="1466373" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="ES">Spain</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate>2013-05-31T00:00:00.000Z</StatusDate><Source id="1466373" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate>2013-09-02T00:00:00.000Z</StatusDate><Source id="1474618" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2399">Adenocarcinoma</Indication><StatusDate>2014-10-09T00:00:00.000Z</StatusDate><Source id="1615536" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="203">Lymphoma</Indication><StatusDate>2011-12-02T00:00:00.000Z</StatusDate><Source id="1249920" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1729">B-cell acute lymphoblastic leukemia</Indication><StatusDate>2011-12-12T00:00:00.000Z</StatusDate><Source id="1244967" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15262">Vernalis plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2004-09-17T00:00:00.000Z</StatusDate><Source id="559635" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="IT">Italy</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate>2013-05-31T00:00:00.000Z</StatusDate><Source id="1466373" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15262">Vernalis plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2003-10-01T00:00:00.000Z</StatusDate><Source id="507273" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21072">Institute of Cancer Research UK</Company><Country id="GB">UK</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2002-04-10T00:00:00.000Z</StatusDate><Source id="446766" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15935">Cancer Research Ventures Ltd</Company><Country id="GB">UK</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2002-04-10T00:00:00.000Z</StatusDate><Source id="446766" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24962">RiboTargets Ltd</Company><Country id="GB">UK</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2002-04-10T00:00:00.000Z</StatusDate><Source id="446766" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2004-09-16T00:00:00.000Z</StatusDate><Source id="559635" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2007-09-03T00:00:00.000Z</StatusDate><Source id="827088" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00179"><Name>ATPase</Name><SwissprotNumbers/></Target><Target id="PTGT-00953"><Name>Hsp 90</Name><SwissprotNumbers><Swissprot>O43109</Swissprot><Swissprot>O44001</Swissprot><Swissprot>O61998</Swissprot><Swissprot>P11500</Swissprot><Swissprot>P20147</Swissprot><Swissprot>P24724</Swissprot><Swissprot>P40292</Swissprot><Swissprot>P41887</Swissprot><Swissprot>P46598</Swissprot><Swissprot>P84577</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>2 references added [&lt;ulink url="utility.reference?i_reference_id=2080766" linkType="reference" linkID="2080766"&gt;2080766&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=2081358" linkType="reference" linkID="2081358"&gt;2081358&lt;/ulink&gt;]							</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="17808">Ligand Pharmaceuticals Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="23137">Novartis AG</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="29469">Cancer Research UK</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="3">Drug - Early Research/Development</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>0</CountActive><CountInactive>1</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>c1ccc2c(c1)ccc(c2c3cc(ccc3O)NS(=O)(=O)c4cc(ccc4Cl)Cl)O</Smiles><Smiles>CCc1cc(c(cc1O)O)c2c(c([nH]n2)C(=O)O)c3ccc4c(c3)OCO4</Smiles><Smiles>CCc1cc(c(cc1O)O)c2c(c[nH]n2)c3c[nH]cn3</Smiles><Smiles>CCNC(=O)c1c(c(on1)c2cc(c(cc2O)O)C(C)C)c3ccc(cc3)CN4CCOCC4</Smiles><Smiles>CCNC(=O)c1c(c(on1)c2cc(cc(c2Cl)O)O)c3ccc(cc3)CN4CCOCC4</Smiles><Smiles>CCNC(=O)c1c(c(n[nH]1)c2cc(c(cc2O)O)Cl)c3ccc(cc3)OC</Smiles><Smiles>CCc1cc(c(cc1O)O)c2c(c([nH]n2)C)c3ccc4c(c3)OCCO4</Smiles><Smiles>CC(=O)c1ccc(cc1)NC(=O)C2C=NN=C2c3cc(c(cc3O)O)Cl</Smiles><Smiles>CN(C)C(=O)CSc1nc(c2c(c[nH]c2n1)C#N)c3cc(c(cc3Cl)Cl)OC</Smiles><Smiles>CCNC(=O)c1c(c(on1)c2cc(c(cc2O)O)C(C)C)c3ccc(cc3)CN4CCOCC4.CS(=O)(=O)O.O</Smiles></StructureSmiles><Deals><Deal id="107371" title="Novartis and Vernalis to research and develop Hsp90 inhibitors for cancer worldwide    "/><Deal id="110105" title="Vernalis collaboration with Cancer Research Ventures and the Institue of Cancer Research on Hsp90 inhibitors    "/></Deals><PatentFamilies><PatentFamily id="1236029" number="WO-2007096194" title="Radio-labeled isoxazole derivatives useful for the labeling and diagnostic of Hsp90 functionality"/><PatentFamily id="1413313" number="WO-2012135588" title="Methods of treating serosal cancer"/><PatentFamily id="1852340" number="WO-2011045396" title="Biomarkers of tumor pharmacodynamic response"/><PatentFamily id="2128592" number="WO-2009047323" title="Organic compounds"/><PatentFamily id="2229982" number="WO-2010020618" title="Susceptibility to HSP90-inhibitors"/><PatentFamily id="2286838" number="WO-2004072051" title="Isoxazole compounds as inhibitors of heat shock proteins"/><PatentFamily id="2512807" number="WO-2013053833" title="2-Carboxamide cycloamino urea derivatives in combination with Hsp90 inhibitors for the treatment of proliferative diseases"/><PatentFamily id="2691531" number="WO-2014036387" title="Methods for diagnosis and treatment of cancer"/><PatentFamily id="2733642" number="WO-2014074580" title="Combination therapy"/><PatentFamily id="2798290" number="WO-2014141194" title="Biomarker"/><PatentFamily id="2826518" number="WO-2014180882" title="Treatment of brain metastasis from cancer"/><PatentFamily id="3046054" number="WO-2015153933" title="Hsp90 inhibitors for the treatment of obesity and methods of use thereof"/><PatentFamily id="3360665" number="WO-2016145219" title="Treatment of peripheral neuropathies"/><PatentFamily id="4122260" number="WO-2018127786" title="Compositions and methods for determining a treatment course of action"/><PatentFamily id="4320917" number="WO-2018232491" title="Mitochondrial targeted releasable linker"/><PatentFamily id="553470" number="WO-2008104595" title="Acid addition salts, hydrates and polymorphs of 5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide and formulations comprising these forms"/><PatentFamily id="873982" number="WO-2010060939" title="Combination of Hsp-90 and herceptin inhibitors"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="13">Product (derivative)</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>4</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>5</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>6</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Universitat de Barcelona" id="1003992"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Universität zu Köln" id="1009493"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Oslo University Hospital" id="1049414"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Ligand Pharmaceuticals Inc" id="17808"/><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Max-Planck Gesellschaft Zur Förderung Der Wissenschaften Ev" id="17962"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="National Research Council of Canada" id="18632"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="US Government" id="20516"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Florida" id="20575"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Toronto" id="20688"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Vanderbilt University" id="20693"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Institute of Cancer Research UK" id="21072"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Memorial Sloan-Kettering Cancer Center" id="22122"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Novartis AG" id="23137"/><CountAsOwner>9</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>9</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Boston Children's Hospital" id="24334"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Harvard Medical School" id="24839"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>2</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Colorado System" id="25520"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Cancer Research UK" id="29469"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>